Mylan (MYL) is expected to report Q2 earnings Thursday, July 30 before market open, with a conference call scheduled for 8:30 am ET.
Analysts are looking for EPS of 30c on revenue of $1.22B. The consensus range is 26c-36c for EPS, and $1.14B-$1.29B for revenue, according to First Call.
The stock has recently been punished on allegations of quality control issues at one of its manufacturing facilities, but in a research note today, Caris said the sell-off creates a buying opportunity. Positive drivers for revenue this quarter could come from new generic products like Depakote, Lamictal and Prilosec, while risks lie chiefly in the integration of the Merck KGaA business. In a June research note Caris said that Mylan would be a very logical acquisition target for Pfizer (PFE). The firm thinks that Mylan could be sold for about $20 per share and it maintains a Buy rating on the stock.